Results 61 to 70 of about 1,678,519 (353)

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.

open access: yesThe Lancet Haematology
BACKGROUND Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT ...
M. Stelljes   +35 more
semanticscholar   +1 more source

Depressive symptoms among patients with schizophrenia in acute and remission phases [PDF]

open access: yesVojnosanitetski Pregled, 2018
Bacground/Aim. Researchers suggest that among people with schizophrenia, the prevalence of depressive symptoms ranges from 7% to 80%. The rate of depressive symptoms among people with schizophrenia varies widely because of the phase of the disease, type ...
Peljto Amir   +3 more
doaj   +1 more source

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

open access: yes, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T.   +5 more
core   +1 more source

Etrolizumab for induction of remission in ulcerative colitis

open access: yesCochrane Database of Systematic Reviews, 2015
Etrolizumab (rhuMAb beta7) is an anti-integrin that selectively targets the β7 subunits of the α4β7 and αEβ7 integrins, which are involved in the pathogenesis of ulcerative colitis.The objectives of this review were to assess the efficacy and safety of etrolizumab for induction of remission in ulcerative colitis.We searched PubMed, MEDLINE, EMBASE, and
Greg, Rosenfeld   +3 more
openaire   +3 more sources

Probiotics for induction of remission in Crohn's disease [PDF]

open access: yesCochrane Database of Systematic Reviews, 2008
Crohn's disease has a high morbidity and there is no known cure. Current treatments have multiple side effects and an effective treatment with minimal side effects is desired. Probiotics have been proposed as such a treatment but their efficacy is undetermined.
Andrew D, Butterworth   +2 more
openaire   +2 more sources

Favorable subset of acute myeloid leukemia with translocation 8;21: An elusive experience

open access: yesMuller Journal of Medical Sciences and Research, 2015
Background: Risk stratification is critical in the management of acute myeloid leukemia (AML) and among the favorable subset translocations known, 8;21 seems elusive in our clinical practice as regards the response remission status. This led us to review
Nusrat Bashir Khan   +5 more
doaj   +1 more source

Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: A retrospective study

open access: yesRheumatology & Autoimmunity, 2021
Background Subjective residual symptoms persist after clinical remission of rheumatoid arthritis (RA) in Japanese patients. Few studies have examined the relationship between these symptoms and subclinical inflammation using high‐sensitivity imaging ...
Masao Nawata   +6 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

open access: yes, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco   +2 more
core   +1 more source

Rheumatoid arthritis [PDF]

open access: yes, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel   +2 more
core   +1 more source

Adalimumab for induction of remission in Crohn's disease

open access: yesCochrane Database of Systematic Reviews, 2017
Adalimumab is an IgG1 monoclonal antibody that targets and blocks tumor necrosis factor-alpha, a pro-inflammatory cytokine involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with CD fail conventional therapy or therapy with biologics or develop significant adverse events.
Mohamad, Abbass   +7 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy